智通财经获悉，周四，Allurion(ALUR.US)股价收涨超21%；截至发稿，股价在盘后交易中进一步飙升80%，此前有消息称该公司计划将其胃球囊减肥产品与GLP-1药物联合进行临床研究。Allurion在市场收盘前十分钟宣布，它正在计划一项研究，将评估Allurion计划与GLP-1药物在改善整体身体成分和肌肉质量方面的作用。该公司指出，虽然 ...

周四，Allurion（ALUR.US）股价收涨超21%；截至发稿，股价在盘后交易中进一步飙升80%，此前有消息称该公司计划将其胃球囊减肥 ...

马萨诸塞州纳蒂克 - 以努力对抗肥胖和保持73%的高毛利率而闻名的Allurion Technologies, Inc. (NYSE: ALUR)今天披露了其计划进行一项临床研究，旨在提高肥胖治疗的效果。根据 InvestingPro ...

Allurion Technologies shares soared 200% Friday as it planned to test its gastric balloon with the key ingredient in popular ...

Allurion, while battling declining revenues, is targeting the loss in muscle mass seen in patients on GLP-1RA therapy.

Allurion catapulted Friday after the company said it plans to test its weight-loss technology with an obesity drug.

Allurion Technologies (ALUR) stock climbed 200% despite a ~7.4M stock and warrants offering announced by the company. Read ...

Investing.com -- Allurion Technologies (NYSE: ALUR)股价飙升350%，此前该公司宣布计划启动一项临床研究，旨在优化GLP-1疗法与Allurion计划结合使用时的肌肉质量。

Shares of Allurion Technologies (NYSE: ALUR) skyrocketed by 350% following the company's announcement of its plans to initiate a clinical study aimed at optimizing muscle mass during GLP-1 therapy in ...

The Allurion swallowable intragastric balloon offers a safe, effective and minimally invasive method of losing weight.

Allurion (ALUR) stock soared 70% after the company announced it is planning to conduct a clinical study of its gastric balloon weight-loss product in combination with GLP-1 drugs.